{"organizations": [], "uuid": "d62d462fabf4105a4ebfd2730f03ba134fc4ffde", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-reata-announces-positive-top-line/brief-reata-announces-positive-top-line-data-for-treatment-of-ph-ild-with-bardoxolone-methyl-from-phase-2-lariat-trial-idUSASC09TB7", "country": "US", "domain_rank": 408, "title": "BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T14:07:00.000+02:00", "replies_count": 0, "uuid": "d62d462fabf4105a4ebfd2730f03ba134fc4ffde"}, "author": "", "url": "https://www.reuters.com/article/brief-reata-announces-positive-top-line/brief-reata-announces-positive-top-line-data-for-treatment-of-ph-ild-with-bardoxolone-methyl-from-phase-2-lariat-trial-idUSASC09TB7", "ord_in_thread": 0, "title": "BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-reata announces positive top-line data for treatment of ph-ild", "sentiment": "negative"}, {"name": "reata pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "reata pharmaceuticals inc", "sentiment": "none"}, {"name": "lariat trial reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 22, 2018 / 12:08 PM / Updated 11 minutes ago BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial Reuters Staff 1 Min Read March 22 (Reuters) - Reata Pharmaceuticals Inc: * REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL * REATA PHARMACEUTICALS INC - RESULTS FROM PHASE 2 LARIAT TRIAL SHOWED SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT * REATA PHARMACEUTICALS INC - NO SAFETY SIGNALS WERE IDENTIFIED IN TRIAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-22T14:07:00.000+02:00", "crawled": "2018-03-22T14:23:14.053+02:00", "highlightTitle": ""}